FULGENT GENETICS INC (FLGT)
US3596641098 - Common Stock
We assign a fundamental rating of 4 out of 10 to FLGT. FLGT was compared to 118 industry peers in the Health Care Providers & Services industry. FLGT has a great financial health rating, but its profitability evaluates not so good. FLGT has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
FLGT had negative earnings in the past year.
In the past year FLGT had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: FLGT reported negative net income in multiple years.
FLGT had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of FLGT (-13.58%) is worse than 72.65% of its industry peers.
Looking at the Return On Equity, with a value of -14.77%, FLGT is in line with its industry, outperforming 46.15% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -14.77% | ||
| ROIC | N/A |
ROA(3y)12.15%
ROA(5y)13.32%
ROE(3y)13.45%
ROE(5y)15.5%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of FLGT (36.10%) is better than 63.25% of its industry peers.
In the last couple of years the Gross Margin of FLGT has declined.
The Profit Margin and Operating Margin are not available for FLGT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.1% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-22.87%
GM growth 5Y-6.3%
2. Health
2.1 Basic Checks
FLGT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FLGT has been increased compared to 1 year ago.
The number of shares outstanding for FLGT has been increased compared to 5 years ago.
The debt/assets ratio for FLGT has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 5.06 indicates that FLGT is not in any danger for bankruptcy at the moment.
The Altman-Z score of FLGT (5.06) is better than 88.89% of its industry peers.
FLGT has a debt to FCF ratio of 1.14. This is a very positive value and a sign of high solvency as it would only need 1.14 years to pay back of all of its debts.
FLGT has a better Debt to FCF ratio (1.14) than 90.60% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that FLGT is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.00, FLGT belongs to the best of the industry, outperforming 88.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.14 | ||
| Altman-Z | 5.06 |
ROIC/WACCN/A
WACC9.13%
2.3 Liquidity
FLGT has a Current Ratio of 6.96. This indicates that FLGT is financially healthy and has no problem in meeting its short term obligations.
FLGT has a better Current ratio (6.96) than 97.44% of its industry peers.
FLGT has a Quick Ratio of 6.96. This indicates that FLGT is financially healthy and has no problem in meeting its short term obligations.
FLGT has a better Quick ratio (6.96) than 97.44% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.96 | ||
| Quick Ratio | 6.96 |
3. Growth
3.1 Past
FLGT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -107.19%.
Looking at the last year, FLGT shows a very negative growth in Revenue. The Revenue has decreased by -53.26% in the last year.
FLGT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 68.33% yearly.
EPS 1Y (TTM)-107.19%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q158.33%
Revenue 1Y (TTM)-53.26%
Revenue growth 3Y-11.81%
Revenue growth 5Y68.33%
Revenue growth Q2Q4.14%
3.2 Future
FLGT is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -25.79% yearly.
FLGT is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.16% yearly.
EPS Next Y-163.71%
EPS Next 2Y-37.2%
EPS Next 3Y-25.79%
EPS Next 5YN/A
Revenue Next Year-1.99%
Revenue Next 2Y6.19%
Revenue Next 3Y7.16%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for FLGT. In the last year negative earnings were reported.
Also next year FLGT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
FLGT's Price/Free Cash Flow ratio is in line with the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 134.04 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
FLGT's earnings are expected to decrease with -25.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-37.2%
EPS Next 3Y-25.79%
5. Dividend
5.1 Amount
FLGT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FULGENT GENETICS INC
NASDAQ:FLGT (5/3/2024, 7:00:00 PM)
After market: 21.5 0 (0%)21.5
+0.26 (+1.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap642.85M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -14.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 36.1% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.96 | ||
| Quick Ratio | 6.96 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-107.19%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-163.71%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-53.26%
Revenue growth 3Y-11.81%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y